Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDI2KZ1C0B)
  Drug Name Methylene blue Drug Info Ozanimod Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antidotes/Mao Inhibitors Selective Immunosuppressants
  Structure

 Mechanism of Methylene blue-Ozanimod Interaction (Severity Level: Major)
     Non-CYP450 enzyme inhibition Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Methylene blue Ozanimod
      Mechanism Monoamine oxidase inhibitor Monoamine oxidase substrate
      Key Mechanism Factor 1
Factor Name Monoamine oxidase Structure Sequence
Protein Family Flavin monoamine oxidase family
Protein Function
Catalyzes the oxidative deamination of primary and some secondary amine such as neurotransmitters, with concomitant reduction of oxygen to hydrogen peroxide and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues (PubMed:20493079, PubMed:8316221, PubMed:18391214, PubMed:24169519). Preferentially oxidizes serotonin (PubMed:20493079, PubMed:24169519). Also catalyzes the oxidative deamination of kynuramine to 3-(2-aminophenyl)-3-oxopropanal that can spontaneously condense to 4-hydroxyquinoline (By similarity).
    Click to Show/Hide
      Mechanism Description
  • Decreased metabolism of Ozanimod caused by Methylene blue mediated inhibition of non-CYP450 enzyme

Recommended Action
      Management Coadministration of ozanimod with MAOIs is considered contraindicated. At least 14 days should elapse between discontinuation of ozanimod and initiation of treatment with MAOIs.

References
1 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.